Clinical Trial: NCT07862114
A Study to Investigate the Effect of Omeprazole and Cyclosporine on Velzatinib in Healthy Participants
Status:
NOT YET RECRUITINGPhase:
Phase 1| Lead Sponsor: | GlaxoSmithKline |
| Information Provided By: | GlaxoSmithKline |
| Last Update Posted: | 2026-10-07 |
Study Overview
Brief Summary
This study will look at how two commonly used medicines, omeprazole and cyclosporine, influence the way the body absorbs, processes, and eliminates velzatinib in healthy volunteers.
Official Title
A Phase 1 Non-Randomized, Open-Label, Parallel-Group Study to Investigate the Effects of Coadministration of the Proton Pump Inhibitor Omeprazole or the P-gp/BCRP Inhibitor Cyclosporine on the Pharmacokinetics, Safety, and Tolerability of Velzatinib in Healthy Participants
Conditions
Healthy Participants, Gastrointestinal Neoplasms
Intervention / Treatment
- Drug: Velzatinib
- Drug: Cyclosporine
- Drug: Omeprazole
Other Study ID Numbers
- 301002
Start Date (Estimated)
2026-10-16
Primary Completion Date (Estimated)
2027-01-12
Study Completion Date (Estimated)
2027-01-12
Enrollment (Estimated)
36
Study Type
Interventional
Phase
Phase 1
| Lead Sponsor: | GlaxoSmithKline |
| Information Provided By: | GlaxoSmithKline |
| Last Update Posted: | 2026-10-07 |
Study Overview
Brief Summary
This study will look at how two commonly used medicines, omeprazole and cyclosporine, influence the way the body absorbs, processes, and eliminates velzatinib in healthy volunteers.
Official Title
A Phase 1 Non-Randomized, Open-Label, Parallel-Group Study to Investigate the Effects of Coadministration of the Proton Pump Inhibitor Omeprazole or the P-gp/BCRP Inhibitor Cyclosporine on the Pharmacokinetics, Safety, and Tolerability of Velzatinib in Healthy Participants
Conditions
Healthy Participants, Gastrointestinal Neoplasms
Intervention / Treatment
- Drug: Velzatinib
- Drug: Cyclosporine
- Drug: Omeprazole
Other Study ID Numbers
- 301002
Start Date (Estimated)
2026-10-16
Primary Completion Date (Estimated)
2027-01-12
Study Completion Date (Estimated)
2027-01-12
Enrollment (Estimated)
36
Study Type
Interventional
Phase
Phase 1